4investors | Börsen-News | Adhoc- und Unternehmensnews |

Aladdin Healthcare Technologies SE: Announces it has entered into a memorandum of understanding with the Imperial Institute of Advanced Technology.

Nachricht vom 12.07.2019 12.07.2019 (www.4investors.de - in Kooperation mit DGAP - EQS Group):






DGAP-Media / 12.07.2019 / 09:38

Aladdin Healthcare Technologies SE Announcesit has entered into a memorandum of understanding with the Imperial Institute of Advanced Technology.
 (BERLIN, Germany and LONDON, England) Day Month, 2019 - Aladdin Healthcare Technologies SE ("Aladdin"), a leading developer of AI healthcare diagnostics and drug discovery applications, today announced it has entered into a memorandum of understanding (MOU) with Imperial Institute of Advanced Technology (IAAT).
 
IAAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies, projects in the field of healthcare from Europe to China, and promoting them in China.
 
The MOU enables Aladdin to host and open its greater China office from a leading science park in Hangzhou China home to multiple unicorn technology companies. The MOU also acts as a prelude to a contractual partnership that will enable Aladdin to jointly develop AI healthcare applications, AI software toolkits for drug discovery, fast track Chinese Food and Drug Administration (CFDA) applications, commercial AI software distribution and access government funding with IAAT. This includes IAAT granting Aladdin access to both its China and International partners and healthcare contacts.
 
Aladdin places real significance on this future partnership as a further access point to the Chinese healthcare market and to further assist in the development and commercialisation of its AI applications.
Wade Menpes-Smith (Chairman)
 About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
 

End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
12.07.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Aladdin Healthcare Technologies SE

Unter den Linden 10

10117 Berlin


Germany
Phone:
030 700140449
E-mail:
info@aladdinid.com
Internet:
www.aladdinid.com
ISIN:
DE000A12ULL2
WKN:
A12ULL
Listed:
Regulated Market in Dusseldorf
EQS News ID:
840473

 
End of News
DGAP Media


840473  12.07.2019 




Weitere DGAP-News von

16.07.2019 - DGAP-News: Immunic, Inc. ernennt Sanjay S. Patel, CFA, zum Chief Financial Officer
16.07.2019 - DGAP-News: Trade Republic Bank GmbH: TRADE REPUBLIC - DEUTSCHLANDS ERSTER MOBILER UND PROVISIONSFREIER BROKER - ERWEITERT HANDELSUNIVERSUM UM DERIVATE UND VERBESSERT ANGEBOT
16.07.2019 - Trade Republic Bank GmbH: TRADE REPUBLIC - DEUTSCHLANDS ERSTER MOBILER UND PROVISIONSFREIER BROKER - ERWEITERT HANDELSUNIVERSUM UM DERIVATE UND VERBESSERT ANGEBOT
16.07.2019 - DGAP-News: financial.de - Philion SE: 'Umsatzversechsfachung auf 300 Mio. Euro realistisch'
16.07.2019 - DGAP-News: Trade Republic Bank GmbH: CREANDUM UND PROJECT A INVESTIEREN IN SERIES A MEHR ALS 10 MILLIONEN EURO IN DIE TRADE REPUBLIC BANK

4investors-News zu

16.05.2019 - TUI Aktie: An dieser Aktienkurs-Marke scheint etwas zu passieren
15.05.2019 - ZEW-Lageindikator folgt der Produktion - Commerzbank Kolumne
15.02.2019 - Deutschland schrammt nur knapp an einer Rezession vorbei - Commerzbank Kolumne
07.02.2019 - Grenke steigert Gewinn - Dividende wird erhöht
07.02.2019 - Osram rauscht in die roten Zahlen - „zahlreiche Unwägbarkeiten”


(Werbung)


All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR